Elanco Product Portfolio
Make use of the filters below to quickly find what you are looking for or browse our full portfolio of innovative products.
Search Resources
Having any questions regarding our products?
Advantage Multi® for Cats
Indications
Advantage Multi for Cats is indicated for the prevention of heartworm disease caused by Dirofilaria immitis. Advantage Multi for Cats kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. Advantage Multi for Cats is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites:
Important Safety Information
CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.
WARNINGS: Do not use on sick or debilitated cats or ferrets. Do not use on underweight cats. (see ADVERSE REACTIONS).
Do not use on cats less than 9 weeks of age and cats or ferrets less than 2 lbs body weight.
PRECAUTIONS: Avoid oral ingestion.
HUMAN WARNINGS: Children should not come in contact with the application site for 30 minutes following application.
For full prescribing information see package label.
Advantage Multi® for Dogs
Indications
Advantage Multi for Dogs is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs. Advantage Multi for Dogs kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis). Advantage Multi for Dogs is indicated for the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis. Advantage Multi for Dogs is also indicated for the treatment and control of the following intestinal parasites:
Important Safety Information
CAUTION: Federal (U.S.A.) law restricts Advantage Multi® for Dogs to use by or on the order of a licensed veterinarian.
WARNING: DO NOT ADMINISTER THIS PRODUCT ORALLY. For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals. (See Contraindications, Warnings, Human Warnings, and Adverse Reactions for more information.)
PRECAUTIONS: Avoid oral ingestion.
CONTRAINDICATIONS: Do not use this product on cats.
HUMAN WARNINGS: Children should not come in contact with the application sites for two (2) hours after application.
For full prescribing information see package label.
Atopica® for Cats
Indication
ATOPICA® for Cats (cyclosporine oral solution) USP MODIFIED is indicated for the control of feline allergic dermatitis as manifested by excoriations (including facial and neck), miliary dermatitis, eosinophilic plaques, and self-induced alopecia in cats at least 6 months of age and at least 3 lbs. in body weight.
Important Safety Information
Do not use in cats with a history or suspicion of malignant disorders, feline leukemia virus (FeLV) or feline immunodeficiency virus (FIV) infection, or hypersensitivity to cyclosporine. Atopica is a systemic immunosuppressant that may increase susceptibility to infection, development of neoplasia, and decrease response to vaccination. Persistent, progressive weight loss may result in hepatic lipidosis; monitoring of body weight is recommended. For use only in cats. Wash hands after administration. People with known hypersensitivity should avoid contact with Atopica. Do not use with other immunosuppressive agents. It is important for cats to avoid exposure to Toxoplasma gondii during treatment. Use with caution in cats with diabetes mellitus or renal insufficiency, and with drugs that affect the P-450 enzyme system. The most common adverse events were vomiting, weight loss, diarrhea or loss of appetite. For full prescribing information see package label.
Atopica® for Dogs
Indication
ATOPICA is indicated for the control of atopic dermatitis in dogs weighing at least 4 pounds and at least 6 months of age.
Important Safety Information
Do not use Atopica in dogs with a history of neoplasia, with a hypersensitivity to cyclosporine, or in reproducing dogs. Atopica is a systemic immunosuppressant that may increase susceptibility to infection and development of neoplasia. For use only in dogs. Capsules should not be broken or opened. Wear gloves during administration and wash hands after administration. Gastrointestinal problems and gingival hyperplasia may occur at the initial dose. For full prescribing information see package label.
Baytril® Antibacterial Injectable Solution for Dogs
Indications
Baytril Antibacterial Injectable Solution is indicated for the management of diseases in dogs associated with bacteria susceptible to enrofloxacin.
Important Safety Information
Enrofloxacin is contraindicated in dogs known to be hypersensitive to quinolones. Quinolone-class drugs should be used with caution in animals with known or suspected Central Nervous System disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation which may lead to convulsive seizures. Quinolone-class drugs have been associated with cartilage erosion in weight-bearing and other forms of arthropathy in immature animals of various species. The use of this product in cats may result in Retinal Toxicity. The use of fluoroquinolones in cats has been reported to adversely affect the retina. Such products should be used with caution in cats. See product label for more information.
Baytril® Otic Emulsion
Indications
Baytril® Otic is indicated as a treatment for canine otitis externa complicated by bacterial and fungal organisms susceptible to enrofloxacin and/or silver sulfadiazine.
Important Safety Information
The use of Baytril® Otic in dogs with perforated tympanic membranes has not been evaluated. Therefore, the integrity of the tympanic membrane should be evaluated before administering this product. If hearing or vestibular dysfunction is noted during the course of treatment, discontinue use. Avoid contact with eyes. In case of contact, immediately flush eyes with copious amounts of water for 15 minutes. The use of Baytril Otic in dogs used for breeding purposes, during pregnancy or in lactating bitches has not been evaluated. Baytril Otic is contraindicated in dogs with suspected or known hypersensitivity to quinolones and/or sulfonamides. During clinical trials, dogs exhibited acute inflammation of the ear canal and pinna. See product label for more information.
Baytril® Antibacterial Tablets for Dogs, Cats
Indications
Baytril Antibacterial Tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. Baytril Antibacterial Tablets are indicated for use in dogs and cats.
Important Safety Information
Quinolone-class drugs should be used with caution in animals with known or suspected Central Nervous System (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation which may lead to convulsive seizures. Quinolone-class drugs have been associated with cartilage erosions in weight-bearing joints and other forms of arthropathy in immature animals of various species.
The use of fluoroquinolones in cats has been reported to adversely affect the retina. Such products should be used with caution in cats. Safety in breeding or pregnant cats has not been established. See product label for more information.
Bexacat™ for Cats
Indication: Bexacat is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin.
Important Safety Information:
Before using this product, it is important to read the entire product insert, including the boxed warning. See package insert for full prescribing information. Cats treated with Bexacat may be at an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis, both of which may result in death. Development of these conditions should be treated promptly, including insulin administration and discontinuation of Bexacat. Do not use Bexacat in cats with diabetes mellitus who have previously been treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus. The use of Bexacat in cats with insulin-dependent diabetes mellitus, or the withdrawal of insulin and initiation of Bexacat, is associated with an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis and death. Sudden onset of hyporexia/anorexia, lethargy, dehydration, diarrhea that is unresponsive to conventional therapy, or weight loss in cats receiving Bexacat should prompt immediate discontinuation of Bexacat and assessment for diabetic ketoacidosis, regardless of blood glucose level. Bexacat should not be initiated in cats with pancreatitis, anorexia, dehydration, or lethargy at the time of diagnosis of diabetes mellitus, as it may indicate the presence of other concurrent disease and increase the risk of diabetic ketoacidosis. Due to risk of severe adverse reactions, do not use Bexacat in cats with evidence of hepatic disease or reduced renal function. Consult a physician in case of accidental ingestion by humans.
Claro® Otic Solution
Indications
Claro is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).
Important Safety Information
Do Not Use in Cats.
Claro should be administered by veterinary personnel. Wear eye protection when administering Claro. Eye injuries, including corneal ulcers, have been reported in humans and dogs associated with head shaking and splatter following administration. Restrain the dog to reduce the potential for splatter of product and accidental eye exposure in people and dogs.
Do not use in dogs with known tympanic membrane perforation. The integrity of the tympanic membrane should be confirmed before administering the product. Claro has been associated with rupture of the tympanic membrane. Reevaluate the dog if hearing loss or signs of vestibular dysfunction are observed during treatment. Owners should be aware that adverse reactions may occur following administration of Claro and should be instructed to observe the dog for signs such as ear pain and irritation, vomiting, head shaking, head tilt, incoordination, eye pain and ocular discharge. Claro is contraindicated in dogs with known or suspected hyper-sensitivity to florfenicol, terbinafine hydrochloride, or mometasone furoate. For full prescribing information see Claro package label.
Credelio® for Cats
Indications
Credelio CAT kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) for one month in cats and kittens 8 weeks of age and older and weighing 2.0 pounds or greater.
Credelio CAT is also indicated for treatment and control of Ixodes scapularis (black-legged tick) infestations for one month in cats and kittens 6 months of age and older and weighing 2.0 pounds or greater.
Important Safety Information
Lotilaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia and seizures. Neurologic adverse reactions have been reported in cats receiving isoxazoline class drugs, even in cats without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders. The safety of Credelio CAT has not been established in breeding, pregnant and lactating cats. The effectiveness of Credelio CAT against Ixodes scapularis in kittens less than 6 months of age has not been evaluated. The most frequently reported adverse reactions are weight loss, tachypnea and vomiting. For full prescribing information see Credelio CAT package insert.
Credelio® for Dogs
Indications for Credelio
Credelio kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Amblyomma americanum (lone star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick) and Rhipicephalus sanguineus (brown dog tick)] for one month in dogs and puppies 8 weeks of age and older and weighing 4.4 pounds or greater.
Important Safety Information (ISI)
Lotilaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving this class of drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of Credelio in breeding, pregnant or lactating dogs has not been evaluated. The most frequently reported adverse reactions are weight loss, elevated blood urea nitrogen, polyuria, and diarrhea. For full prescribing information see Credelio product label.
Deramaxx®
Indications
DERAMAXX Chewable Tablets are indicated for the control of pain and inflammation associated with osteoarthritis in dogs.
Important Safety Information
Not for use in humans. For use in dogs only. Keep this and all medications out of the reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. As with all drugs in this class, side effects involving the digestive system, kidneys or liver may occur. These are normally mild, but may be serious. Pet owners should discontinue therapy and contact their veterinarian immediately if side effects occur. All dogs should undergo a thorough history and physical examination before using DERAMAXX. Regular monitoring is recommended. Use with other NSAIDs or corticosteroids should be avoided. Please see the product label for full prescribing information.
Elura® for Cats
INDICATION: Elura® is indicated for management of weight loss in cats with chronic kidney disease.
IMPORTANT SAFETY INFORMATION: For oral use in cats only. Do not use in cats that have a hypersensitivity to capromorelin or in cats with hypersomatotropism (acromegaly). Elura® may increase serum glucose for several hours after dosing; use in cats with current or historical diabetes mellitus has not been evaluated and may not be appropriate. Use with caution in cats that may have cardiac disease, severe dehydration or hepatic dysfunction. Elura® has not been evaluated in cats younger than 5 months of age or in breeding, pregnant or lactating cats. The most common adverse reactions included vomiting, hypersalivation, inappetence, behavior change and lethargy. Please see Elura® product label for full prescribing information.
Entyce® for Dogs
The effectiveness of Entyce has not been studied beyond 4 days in the clinical study.
INDICATION: For appetite stimulation in dogs.
IMPORTANT SAFETY INFORMATION: For use in dogs only. Do not use in dogs that have a hypersensitivity to capromorelin. Use with caution in dogs with hepatic dysfunction or renal insufficiency. The safe use of Entyce has not been evaluated in breeding, pregnant or lactating dogs. The most common adverse reactions included diarrhea, vomiting, elevated blood urea nitrogen, polydipsia and hypersalivation.
Please see Entyce product label for full prescribing information.
Galliprant®
Indication
Galliprant is an NSAID that controls pain and inflammation associated with osteoarthritis in dogs.
Important Safety Information
Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. See product label for full prescribing information.
Interceptor® Flavor Tabs (milbemycin oxime) for Dogs and Cats
Indications for Dogs
Indications: INTERCEPTOR is indicated for use in the prevention of heartworm disease caused by Dirofilaria immitis, the control of adult Ancylostoma caninum (hookworm), and the removal and control of adult Toxocara canis and Toxascaris leonina (roundworms) and Trichuris vulpis (whipworm) infections in dogs and in puppies four weeks of age or greater and two pounds body weight or greater.
Important Safety Information for Dogs
Dogs and cats should be tested for existing heartworm infection prior to use. In a small percentage of treated dogs, digestive and neurologic side effects may occur. Safety in heartworm-positive cats has not been established. Safety in breeding, pregnant and lactating queens and breeding toms has not been established. View full product label for complete safety information.
Indications for Cats
INTERCEPTOR for Cats is indicated for use in the prevention of heartworm disease caused by Dirofilaria immitis, and the removal of adult Ancylostoma tubaeforme (hookworm) and Toxocara cati (roundworm) in cats and kittens six weeks of age or greater and 1.5 Ibs. body weight or greater.
Important Safety Information for Cats
Dogs and cats should be tested for existing heartworm infection prior to use. In a small percentage of treated dogs, digestive and neurologic side effects may occur. Safety in heartworm-positive cats has not been established. Safety in breeding, pregnant and lactating queens and breeding toms has not been established. View full product label for complete safety information.
Interceptor® Plus for Dogs
Indications
Interceptor Plus is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of adult roundworm (Toxocara canis, Toxascaris leonina), adult hookworm (Ancylostoma caninum), adult whipworm (Trichuris vulpis), and adult tapeworm (Taenia pisiformis, Echinococcus multilocularis, Echinococcus granulosus and Dipylidium caninum) infections in dogs and puppies 6 weeks or older and 2 pounds or greater.
Important Safety Information
Treatment with fewer than 6 monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention. Prior to administration of Interceptor Plus, dogs should be tested for existing heartworm infections. The safety of Interceptor Plus has not been evaluated in dogs used for breeding or in lactating females. The following adverse reactions have been reported in dogs after administration of milbemycin oxime or praziquantel: vomiting, diarrhea, depression/lethargy, ataxia, anorexia, convulsions, weakness, and salivation. For full prescribing information see Interceptor Plus package label.
K9 Advantix® II for Dogs
It is a violation of Federal Law to use this product in a manner inconsistent with its labeling. Do not contaminate feed or food.
Restrictions:
- Do not allow children to apply product.
- Do not have contact or allow children to have contact with treated area until completely dry.
- Do not apply an excessive amount of solution at any one spot that could cause some of the solution to run off the side of the dog.
- Do not get this product in your dog’s eyes or allow your dog to ingest this product.
- Dogs should be dry prior to application and remain dry for 24 hours after application for product to work effectively.
- Do not use on cats. Keep cats away from treated dogs for 24 hours.
For further information, please refer to the Product Label
Nocita® for Dogs and Cats
Indications
For single-dose infiltration into the surgical site to provide local postoperative analgesia for cranial cruciate ligament surgery in dogs. For use as a peripheral nerve block to provide regional postoperative analgesia following onychectomy in cats.
Important Safety Information
NOCITA is for use in dogs and cats only. Do not administer concurrently with bupivacaine HCl, lidocaine or other amide local anesthetics. The safe use of NOCITA in dogs and cats with cardiac disease or with hepatic or renal impairment has not been evaluated. The safe use in dogs or cats younger than 5 months of age, that are pregnant, lactating, or intended for breeding has not been evaluated. The most common adverse reactions in dogs were discharge from incision, incisional inflammation and vomiting. The most common adverse reactions in cats were elevated body temperature and infection or chewing/licking at the surgical site. Click here to view full product label.
Onsior® for Cats
Indications for Cats
ONSIOR® tablets for Cats are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy and castration, in cats ≥ 5.5 lbs and ≥ 4 months of age; for up to a maximum of 3 days.
ONSIOR® injection is indicated for the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy and castration in cats ≥ 4 months of age; for up to a maximum of 3 days.
Important Safety Information for Cats
Do not use in cats that have hypersensitivity to robenacoxib or known intolerance to NSAIDs. Do not administer Onsior® tablets or injection in conjunction with any other NSAID or corticosteroid. Do not use for more than 3 days. A thorough history and physical exam including appropriate testing should be conducted before initiation of a NSAID therapy. Owners should be advised to observe for signs of potential drug toxicity. Stop administration of ONSIOR® if appetite decreases or if the cat becomes lethargic. The use of ONSIOR® has not been evaluated in cats used for breeding, or in pregnant or lactating cats or in cats with cardiac disease. As a class, cyclo-oxygenase inhibitory NSAIDS may be associated with gastrointestinal, renal, and hepatic toxicity. For full prescribing information see label links below.
ONSIOR® injection: For subcutaneous use in cats ≥ 4 months of age. Safety has not been demonstrated for intravenous or intramuscular administration. The most common adverse reactions were incision site infection, increased incision site bleeding, vomiting, inappetence and lethargy.
ONSIOR® tablets for Cats: For oral use in cats ≥ 5.5 lbs and ≥ 4 months of age only. The most common adverse events are anorexia, depression, vomiting, elevated BUN, elevated creatinine, and renal insufficiency/failure.
Profender® for Cats
Indications
PROFENDER Topical Solution is indicated for the treatment and control of hookworm infections caused by Ancylostoma tubaeforme (adults, immature adults, and fourth stage larvae), roundworm infections caused by Toxocara cati (adults and fourth stage larvae), and tapeworm infections caused by Dipylidium caninum (adults) and Taenia taeniaeformis (adults) in cats.
Important Safety Information:
CAUTION: Federal law (U.S.A.) restricts this drug to use by or on the order of a licensed veterinarian.
Topical Solution for the treatment and control of hookworm, roundworm and tapeworm infections in cats and kittens that are at least 8 weeks of age and weigh at least 2.2 lbs (1 kg).
HUMAN WARNINGS:
Not for human use. Keep out of reach of children.
To prevent accidental ingestion of the product, children should not come in contact with the application site for twenty-four (24) hours while the product is being absorbed. Pregnant women, or women who may become pregnant, should avoid direct contact with, or wear disposable gloves when applying, this product. Studies performed in rats and rabbits suggest that emodepside may interfere with fetal development in those species.
PROFENDER Topical Solution may be irritating to skin and eyes. Reactions such as facial, tongue and hand swelling have been reported in humans in rare instances. Avoid contact with the application area while it is wet and wash hands thoroughly with soap and warm water after handling. People with known hypersensitivity to butylhydroxyanisole, emodepside or praziquantel should administer the product with caution. If the product accidentally gets into eyes, flush thoroughly with water. May be harmful if swallowed. In case of accidental ingestion or if skin or eye irritation occurs, call a poison control center or physician for treatment advice.
The Safety Data Sheet (SDS) provides additional occupational safety information. For customer service or to obtain product information, including the SDS, call 1- 800-633-3796. For medical emergencies or to report an adverse reaction, call 1- 800-422-9874.
quellin®
Indications
quellin is indicated for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs.
Important Safety Information
For use in dogs only. Do not use in cats. All dogs should undergo a thorough history and physical examination before initiation of NSAID therapy. Appropriate laboratory tests to establish hematological and serum biochemical baseline data prior to, and periodically during, administration of any NSAID should be considered. Owners should be advised to observe for signs of potential drug toxicity. For complete safety information, view the product label.
Rabvac®
Always read, understand and follow the label and use directions.
Seresto® for Cats
Scratching may be observed occasionally in cats that are not used to wearing collars during the first few days after fitting. Clients should ensure the collar is not fitted too tightly. Slight hair loss and mild skin reactions due to the mechanical irritation of the collar may occur at the application site; this usually clears within one or two weeks without the need for collar removal.
Do not open until ready to use. Keep out of reach of children; do not let children play with the collar or reflectors. Choking hazard; contains small parts.
For external use on cats only. Do not use on other animals. Not intended for use on humans.
For more information, please refer to the Product Label.
Seresto® for Dogs
Occasionally, scratching may be observed in dogs who are not used to wearing collars during the first few days after fitting. Clients should ensure the collar is not fitted too tightly. Slight hair loss and mild skin reactions due to the mechanical irritation of the collar may occur at the application site; this usually clears within one or two weeks without the need for collar removal.
Keep the collar in the bag and in the outer packaging until use. Keep out of reach of children. Choking hazard — contains small parts. For external use on dogs only. Do not use Seresto® for Dogs on other animals.
For more information, please refer to the Product Label.
Surolan®
Indication
SUROLAN® (miconazole nitrate, polymyxin B sulfate, prednisolone acetate) is indicated for the treatment of canine otitis externa associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).
Important Safety Information
Do not use Surolan® otic suspension in dogs with known perforated tympanum or with drugs known to induce ototoxicity. If overgrowth of non-susceptible bacteria or fungi occurs, treatment should be discontinued and appropriate therapy instituted. Long-term use of topical otic corticosteroids has been associated with adrenocortical suppression and iatrogenic hypoadrenocorticism in dogs. The safe use of Surolan® in breeding animals has not been evaluated. Please see product label for full prescribing information.
Tanovea® for Dogs
INDICATION: Tanovea is indicated for the treatment of lymphoma in dogs.
IMPORTANT SAFETY INFORMATION: Tanovea is not for use in humans. Keep out of reach of children. Do not come into direct contact with Tanovea. Wear chemotherapy-resistant gloves to prevent contact with feces, urine, vomit, and saliva of treated dogs for five days following treatment. Rabacfosadine is cytotoxic and may cause birth defects and affect female and male fertility. Pregnant women, those who may become pregnant, and nursing women should not handle, prepare or administer the product. Tanovea is associated with life-threatening or fatal pulmonary fibrosis. Monitoring for signs of pulmonary dysfunction is recommended. Do not use in dogs with pulmonary fibrosis, a history of chronic pulmonary disease that could lead to fibrosis, or in breeds with a predisposition to this condition such as West Highland White Terriers. Use with caution in other terrier breeds. Do not use in dogs that are pregnant, lactating, or intended for breeding. Tanovea is associated with dermatopathies which can worsen with subsequent treatment; careful monitoring is recommended. Tanovea can cause neutropenia with nadir around seven days post-treatment. Dogs should be frequently monitored for evidence of neutropenia during treatment. Most common adverse reactions included diarrhea, decreased appetite, emesis, lethargy, weight loss and neutropenia.
Please see Tanovea product label for full prescribing information.
Trifexis®
Indications
Trifexis is indicated for the prevention of heartworm disease (Dirofilaria immitis). Trifexis® kills fleas and is indicated for the prevention and treatment of flea infestations (Ctenocephalides felis), and the treatment and control of adult hookworm (Ancylostoma caninum), adult roundworm (Toxocara canis and Toxascaris leonina) and adult whipworm (Trichuris vulpis) infections in dogs and puppies 8 weeks of age or older and 5 pounds of body weight or greater.
Important Safety Information
Serious adverse reactions have been reported following concomitant extra-label use of ivermectin with spinosad alone, one of the components of Trifexis. Treatment with fewer than three monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention. Prior to administration of Trifexis, dogs should be tested for existing heartworm infection. Use with caution in breeding females. The safe use of Trifexis® in breeding males has not been evaluated. Use with caution in dogs with pre-existing epilepsy. The most common adverse reactions reported are vomiting, depression/lethargy, pruritus, anorexia, and diarrhea. To ensure heartworm prevention, dogs should be observed for one hour after administration. If vomiting occurs within one hour of administration, redose. Puppies less than 14 weeks of age may experience a higher rate of vomiting. For full prescribing information see Trifexis product label.
TruCan™ Product Labels
TruFel™ Product Labels
Varenzin-CA1
INDICATION:
Varenzin-CA1 is indicated for the control of nonregenerative anemia associated with chronic kidney disease (CKD) in cats.
IMPORTANT SAFETY INFORMATION:
For oral use in cats only. Keep this drug, including used syringes, out of reach of children. Wash hands immediately after use. In case of accidental ingestion, seek medical advice immediately. Women who are pregnant or may become pregnant should administer the product with caution. Varenzin-CA1 should not be administered to cats that are pregnant, lactating or intended for breeding or to cats with known hypersensitivity to molidustat or to any of the inactive ingredients. Use with caution in cats with a history of seizures and in cats predisposed to thromboembolic disease. Hematocrit (HCT) or packed cell volume (PCV) levels should be monitored regularly as polycythemia may result from use of Varenzin-CA1. Varenzin-CA1 has not been evaluated in cats less than 1 year of age. The most common adverse reactions included vomiting, increases in systolic blood pressure and mild transient increase in serum potassium. View product label.
Veraflox® for Cats
INDICATION:
Veraflox is indicated for the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida, Streptococcus canis, Staphylococcus aureus, Staphylococcus felis and Staphylococcus pseudintermedius.
CAUTION:
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals. For use in cats only.
PRECAUTIONS:
The use of fluoroquinolones in cats has been associated with the development of retinopathy and/or blindness. Such products should be used with caution in cats.
For full prescribing information see product label.
Zorbium® for Cats
Indications
ZORBIUM is indicated for the control of postoperative pain associated with surgical procedures in cats.
Important Safety Information
Before using ZORBIUM (buprenorphine transdermal solution), read the entire package labelincluding the Boxed Human Warning.
ZORBIUM contains buprenorphine, an opioid that exposes humans to risks of misuse, abuse and addiction, which can lead to overdose and death. Use of buprenorphine may lead to physical dependence. The risk of abuse by humans should be considered when storing, administering and disposing of ZORBIUM. Serious, life-threatening or fatal respiratory depression may occur with accidental exposure to or with misuse or abuse of ZORBIUM. ZORBIUM should only be administered by veterinarians or veterinarian technicians who are trained in the handling of potent opioids. Accidental exposure to even one tube of ZORBIUM, especially in children, can result in a fatal overdose.
ZORBIUM is for topical application in cats only. Do not come into direct contact with ZORBIUM. Wear impermeable latex or nitrile gloves, protective glasses and a laboratory coat when applying ZORBIUM. Following application to the cat, allow a minimum drying time of 30 minutes before direct contact with the application site. Do not administer to cats with a known hypersensitivity to buprenorphine hydrochloride, any inactive ingredients of ZORBIUM, or known intolerance to opioids. Do not apply ZORBIUM if the application site at the dorsal cervical area has diseased or injured skin, or to anatomic areas other than the dorsal cervical area because absorption characteristics may be different. Body temperature should be monitored postoperatively. Most common adverse reactions during anesthesia were hypothermia, hypotension and hypertension, and after anesthetic recovery were hypothermia, hyperthermia and sedation. The safe use of ZORBIUM has not been evaluated in debilitated cats; those with renal, hepatic, cardiac or respiratory disease; pregnant, lactating or breeding cats; in cats younger than four months old; or in cats <2.6 lbs. or >16.5 lbs. For full prescribing information see product label.
